Discounted Cash Flow (DCF) Analysis Levered
AIM ImmunoTech Inc. (AIM)
$0.441
-0.02 (-4.30%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 0.37 | 0.14 | 0.16 | 0.13 | 0.14 | 0.12 | 0.10 | 0.09 | 0.08 | 0.06 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -10.64 | -9.07 | -10.37 | -13.96 | -16.11 | -9.04 | -7.72 | -6.60 | -5.64 | -4.82 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -0.13 | -0.36 | -0.60 | -0.63 | -0.27 | -0.32 | -0.27 | -0.23 | -0.20 | -0.17 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -10.77 | -9.43 | -10.96 | -14.60 | -16.38 | -9.36 | -8 | -6.83 | -5.84 | -4.99 |
Weighted Average Cost Of Capital
| Share price | $ 0.441 |
|---|---|
| Beta | -0.135 |
| Diluted Shares Outstanding | 48.05 |
| Cost of Debt | |
| Tax Rate | -8.44 |
| After-tax Cost of Debt | -57.11% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 3.960 |
| Total Debt | 0.84 |
| Total Equity | 21.19 |
| Total Capital | 22.03 |
| Debt Weighting | 3.80 |
| Equity Weighting | 96.20 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 0.37 | 0.14 | 0.16 | 0.13 | 0.14 | 0.12 | 0.10 | 0.09 | 0.08 | 0.06 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -10.64 | -9.07 | -10.37 | -13.96 | -16.11 | -9.04 | -7.72 | -6.60 | -5.64 | -4.82 |
| Capital Expenditure | -0.13 | -0.36 | -0.60 | -0.63 | -0.27 | -0.32 | -0.27 | -0.23 | -0.20 | -0.17 |
| Free Cash Flow | -10.77 | -9.43 | -10.96 | -14.60 | -16.38 | -9.36 | -8 | -6.83 | -5.84 | -4.99 |
| WACC | ||||||||||
| PV LFCF | -9.21 | -7.74 | -6.51 | -5.47 | -4.60 | |||||
| SUM PV LFCF | -33.53 |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 1.64 |
| Free cash flow (t + 1) | -5.09 |
| Terminal Value | 1,414.17 |
| Present Value of Terminal Value | 1,303.70 |
Intrinsic Value
| Enterprise Value | 1,270.17 |
|---|---|
| Net Debt | -26.22 |
| Equity Value | 1,296.39 |
| Shares Outstanding | 48.05 |
| Equity Value Per Share | 26.98 |